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Many compounds and genetic manipulations are claimed to confer resistance to obesity
in rodents by raising energy expenditure. Examples taken from recent and older literature,
demonstrate that such claims are often based on measurements of energy expenditure
after body composition has changed, and depend on comparisons of energy expenditure
divided by body weight. This is misleading because white adipose tissue has less influence
than lean tissue on energy expenditure. Application of this approach to human data would
suggest that human obesity is usually due to a low metabolic rate, which is not an
accepted view. Increased energy expenditure per animal is a surer way of demonstrating
thermogenesis, but even then it is important to know whether this is due to altered body
composition (repartitioning), or increased locomotor activity rather than thermogenesis
per se. Regression analysis offers other approaches. The thermogenic response to some
compounds has a rapid onset and so cannot be due to altered body composition. These
compounds usually mimic or activate the sympathetic nervous system. Thermogenesis
occurs in, but may not be confined to, brown adipose tissue. It should not be assumed
that weight loss in response to these treatments is due to thermogenesis unless there
is a sustained increase in 24-h energy expenditure. Thyroid hormones and fibroblast
growth factor 21 also raise energy expenditure before they affect body composition. Some
treatments and genetic modifications alter the diurnal rhythm of energy expenditure. It is
important to establish whether this is due to altered locomotor activity or efficiency of
locomotion. There are no good examples of compounds that do not affect short-term
energy expenditure but have a delayed effect. How and under what conditions a genetic
modification or compound increases energy expenditure influences the decision on
whether to seek drugs for the target or take a candidate drug into clinical studies.
Keywords: thermogenesis, energy expenditure, leanness, anti-obesity drug, genetically modified mouse,
sympathomimetic, brown adipose tissue, leptin
INTRODUCTION
Despite the continuing rise in the worldwide prevalence of obesity
and the vast sales that a safe and effective drug for this disorder
might achieve, many pharmaceutical companies have been dis-
inclined to invest in research and development in this field in
recent years because the task seemed near impossible. Following
the withdrawal of fenfluramine and dexfenfluramine in 1997, pri-
marily because they caused heart valve disease, sibutramine, and
rimonabant offered a glimmer of hope, but either they never
reached the US or European markets, or they were soon with-
drawn owing to adverse cardiovascular or CNS side-effects. Only
the pancreatic lipase inhibitor orlistat remains for long term phar-
macotherapy, and its efficacy (about 3 kg weight loss compared
to placebo when used at its highest approved dose) is limited
(Rucker et al., 2007).
Some optimism has returned recently following the approval
by the US Food and Drug Administration (FDA) of the combi-
nation of the anti-epileptic drug topiramate in combination with
the “anorectic” drug phentermine under the brand nameQsymia.
The European Medicines Agency has rejected Qsymia, however.
Soon after its approval of Qsymia, the FDA also approved the
selective 5HT2C receptor agonist lorcaserin (Wong et al., 2012).
Looking to the future, approval of the glucagon-like peptide-1
analogue liraglutide may be helped by it being already marketed
for the treatment of type 2 diabetes, albeit at a lower dose than
that being evaluated in Phase III clinical trials for obesity.
Apart from orlistat, the primary mechanism of which is to
reduce energy absorption rather than intake, these drugs have all
been perceived as anorectic agents. Is this entirely true? Studies
in rodents suggest that the anti-obesity effects of many “anorec-
tic” drugs are partly, or even entirely, due to increased energy
expenditure (“thermogenesis”) (Arch, 1981; Day and Bailey,
1998; Picard et al., 2000; Herling et al., 2008). There is noth-
ing new in the concept of thermogenic drugs: two of the earliest
drugs for obesity of the scientific era—dinitrophenol and thy-
roid hormones—stimulate thermogenesis (Clapham and Arch,
2007).
It is important to understand how evidence that compounds
are thermogenic in rodents has been obtained and whether this
evidence translates to humans, because the question “Is it anorec-
tic or thermogenic?” will continue to be asked of new drugs, drug
candidates and drug targets. This question is especially pertinent
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because interest in thermogenic drugs and drug targets has been
rekindled by new evidence that brown adipose tissue can be
active in adult humans and the discovery of new targets for drugs
that might augment and activate brown adipose tissue (Fruhbeck
et al., 2009; Wu et al., 2011; Bostrom et al., 2012; Fournier et al.,
2012; Ye et al., 2012). The role of brown adipose tissue is to oxi-
dise fat without coupling the energy released to the synthesis of
ATP. The purpose of this uncoupling is either to produce heat (in
which case fat loss can be seen as a by-product) or to regulate body
fat stores (with thermogenesis as a by-product). Thus, drugs that
target brown adipose tissue should be thermogenic.
The aim of this article is to discuss how thermogenesis in
response to treatment with a drug can be detected. In addition,
since targets for thermogenic drugs are often validated by inves-
tigating the phenotype of genetically modified mice, it considers
how to ascertain whether leanness in a genetically modified ani-
mal is associated with increased energy expenditure. Examples of
various approaches are taken from both old and recent literature.
We argue that some of the claims are unjustified. The issue of
how to compare the energy expenditure of lean and obese rodents
has been discussed extensively elsewhere (Arch et al., 2006; Butler
and Kozak, 2010; Kaiyala et al., 2010; Cannon and Nedergaard,
2011; Even and Nadkarni, 2012; Tschop et al., 2012; Speakman,
2013), so we shall not repeat all the arguments, but raise points
that others may not have addressed. We are among those who
object strongly to the expression of energy expenditure relative
to body weight or body weight0.75, for the purpose of compar-
ing lean and obese rodents. This is standard practice in most
journals and apparently accepted without question by most ref-
erees, but it is often misleading or simply wrong—particularly
and paradoxically since intake is almost invariably expressed on
a “per animal” basis. Thus, a continuing theme is the dismissal
of claims based on this practice. The claims that we have selected
to dismiss are merely examples, often taken from recent litera-
ture. A number of other examples have been described in previous
publications (Butler and Kozak, 2010; Arch, 2011), but even tak-
ing the articles together, these are only the tip of the iceberg.
The translation of studies in rodents to humans is also briefly
considered.
ACUTE STIMULATION OF ENERGY EXPENDITURE
RAPID ONSET RESPONSE TO COMPOUNDS
Sympathomimetic agents
It is easiest to make the case for a compound being thermo-
genic if energy expenditure rises rapidly, ideally within minutes
after its administration. This has two advantages over other types
of evidence: energy expenditure prior to administration of the
compound provides a baseline control, and interpretation of
data is not complicated by changes in body weight or compo-
sition, because these are no different for the compound- and
vehicle-treated animals.
Classic examples of such evidence are the rises in energy
expenditure within an hour (or minutes if given intra-
venously) following administration of noradrenaline, and sym-
pathomimetic compounds such as phentermine, ephedrine and
β3-adrenoceptor agonists (Arch, 1981; Arch et al., 1982, 1984;
Wilson et al., 1984; Holloway et al., 1991; Granneman et al.,
2003; Kong et al., 2004). The rapid increases in energy expen-
diture and brown adipose tissue temperature elicited by caffeine
(Arch et al., 1987; Yoshioka et al., 1990), theophylline (Strubelt
and Siegers, 1969), green tea (Dulloo et al., 2000; Choo, 2003)
and nicotine (Wellman et al., 1986; Collins et al., 1996a) are
also probably mainly a consequence of their raising sympathetic
activity, though othermechanisms—including increased locomo-
tor activity in response to caffeine—may contribute (Arch et al.,
1987). Sibutramine similarly elicits a slightly delayed, increase
in energy expenditure in rodents as a consequence of it activat-
ing the sympathetic nervous system. It took about an hour for
this effect to become statistically significant following intraperi-
toneal administration to rats, presumably because sibutramine
must increase synaptic serotonin and noradrenaline concentra-
tions in the hypothalamus before the sympathetic nervous system
is activated. The simultaneous injection of the noradrenaline re-
uptake inhibitor nisoxetine and the serotonin re-uptake inhibitor
fluoxetine stimulated energy expenditure with a similar delay
(Connoley et al., 1999). A more recent example is that intrac-
erebroventricular administration of bone morphogenetic protein
8B elicited an increase in sympathetic activity in brown adi-
pose tissue and in core temperature within an hour, but energy
expenditure was not measured directly (Whittle et al., 2012). By
contrast, zinc-α2-glycoprotein (ZAG), despite being claimed to
be a β3-adrenoceptor agonist (Russell et al., 2002; Russell and
Tisdale, 2012a), did not elicit a rapid rise in energy expenditure
in our hands (Wargent et al., 2013), and has not been reported
to do so by others. Nevertheless, it may raise energy expen-
diture over a period of days and reduce body weight and fat
independently of any effect on food intake (Russell and Tisdale,
2011a,b).
A possible reason why sympathomimetic agents have such a
marked thermogenic effect is that they stimulate the mobilization
of fatty acids as well as their combustion. Thus, a β3-adrenoceptor
agonist stimulated thermogenesis in mice that expressed the β3-
adrenoceptor in brown and white adipose tissue (and no other
tissue), but it had little effect when the β3-adrenoceptor was
expressed in brown adipose tissue only—the brown adipocytes
seemed to be starved of fuel to burn (Grujic et al., 1997). Similarly,
antilipolytic agents, such as nicotinic acid, reduce thermogene-
sis in response to catecholamines and β-adrenoceptor agonists
(Kennedy and Ellis, 1969; Lafrance et al., 1979; Schiffelers et al.,
1998), and the thermogenic effects of β3-adrenoceptor agonists
are less prolonged in lean or lipoatrophic mice than in obese mice
(Arch and Ainsworth, 1983a; Gavrilova et al., 2000).
It is reasonable to consider whether any compound that elic-
its a rapid increase in energy expenditure does so by activating the
sympathetic nervous system. One such compound is the cannabi-
noid 1-receptor (CB1-R) antagonist rimonabant, which elicits
a rapid increase in energy expenditure in rats (Herling et al.,
2008; Kunz et al., 2008), though this has not been demonstrated
in humans. Antagonism of the CB1-R promotes noradrenaline
release at peripheral sympathetic nerves (Marsicano and Lutz,
2006; Mnich et al., 2010) and activates sympathetic activity via a
central mechanism (Verty et al., 2009). It is therefore possible that
the acute thermogenic effect of rimonabant in rodents is medi-
ated by the sympathetic nervous system. Other examples of rapid
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thermogenic responses that are probably mediated by raised sym-
pathetic activity are those to a catalytic antibody that hydrolyzed
the octanoyl moiety of ghrelin (Mayorov et al., 2008; Arch, 2011),
to amylin (Osaka et al., 2008) and to thyrotrophin-releasing hor-
mone (Schuhler et al., 2007). In the case of thyrotrophin-releasing
hormone, evidence for the involvement of the sympathetic ner-
vous system is that its intracerebroventricular infusion increased
noradrenaline turnover in brown adipose tissue, and thermogen-
esis was suppressed by sympathetic denervation of brown adipose
tissue (Shintani et al., 2005).
The thermogenic effects of β3-adrenoceptor agonists and
amylin, and the anti-obesity effect of ZAG are reduced or pre-
vented by the β-adrenoceptor antagonist propranolol (Arch and
Ainsworth, 1983a; Arch et al., 1991; Osaka et al., 2008; Russell and
Tisdale, 2012a,b). We have suggested that the anti-obesity effect
of ZAG may be due to central activation of the sympathetic ner-
vous system, rather than direct activation of the β3-adrenoceptor
and this is why its anti-obesity effect is blocked by propranolol
(Wargent et al., 2013). Propranolol also blocked thermogene-
sis in response to the centrally acting sympathomimetic agents
caffeine and theophylline (Strubelt and Siegers, 1969). Doses of
β-adrenoceptor antagonists have to be high to block the rodent
β3-adrenoceptor and there is therefore a risk that they might elicit
non-β-adrenoceptor-mediated effects.
Alternative approaches to investigating the role of the sym-
pathetic nervous system can be illustrated by considering stud-
ies on leptin. Intracerebroventricular administration of leptin
increases energy expenditure in ob/ob mice within 3 h (Mistry
et al., 1997). In rats, intracerebroventricular injection of leptin
increased body temperature after an hour; peripheral administra-
tion took 3 h (Luheshi et al., 1999). Subcutaneous administration
has been shown to increase energy expenditure within 12 h in
suckling rats (Stehling et al., 1996) and 2 days when infused
by minipump in normal mice (Asensio et al., 2008). Leptin
increases noradrenaline turnover in brown and white adipose tis-
sue (Collins et al., 1996b) and electrical activity in sympathetic
nerves (Dunbar et al., 1997; Hausberg et al., 2002). None of this
shows whether increased sympathetic activity is responsible for
any of the thermogenic activity of leptin, however. Better evidence
is that the thermogenic effect on days 2–6 of subcutaneously
infused leptin was reduced by about 50% in mice that lack all
three β-adrenoceptors (betaless mice) (Asensio et al., 2008). Work
in Lep◦b/Lep◦b mice that also lack UCP-1 suggests that elevation
of plasma tri-iodothyronine by leptin and activation of sarcoen-
doplasmic reticulum Ca2+ ATPase may contribute to some of the
remaining thermogenic effect of leptin (Ukropec et al., 2006b).
Studies on the role of the sympathetic nervous system in the
anti-obesity effect of leptin are described in section Detection of
Non-Acute Thermogenesis.
Despite these inconclusive results with leptin, it is advisable to
investigate whether a prospective thermogenic anti-obesity com-
pound is as effective in sympathectomised, betaless, or individual
β-adrenoceptor knockout mice as it is in normal mice. This infor-
mation may help in the design of clinical studies (see section
Translation of Rodent Findings to Humans). It might also be
useful to evaluate compounds in mice that lack brown adipose
tissue (Lowell et al., 1993), though it should not be assumed
that all sympathetically-mediated thermogenesis in rodents is in
brown adipose tissue (Thurlby and Ellis, 1986). Even those who
argue that all adaptive thermogenesis is in brown adipose tissue
find that much of the thermogenic response to noradrenaline in
mice that are fed on a normal diet and housed at thermoneutrality
remains in mice that lack uncoupling protein-1 (UCP-1), thereby
lacking the defining protein of brown adipose tissue (Feldmann
et al., 2009). They argue that the UCP-1-independent thermo-
genic effect of noradrenaline is a pharmacological, non-adaptive
effect that takes place in tissues other than brown adipose tis-
sue, rather than a physiological effect (Cannon and Nedergaard,
2011). These arguments are consistent with adaptive thermo-
genesis being exclusive to brown adipose tissue (Cannon and
Nedergaard, 2011) and with reports that thermogenic doses
of the β-adrenoceptor agonist isoprenaline and the sympath-
omimetic drug ephedrine failed to activate brown adipose tissue
in humans, although cold exposure did (Cypess et al., 2012;
Vosselman et al., 2012). A non-physiologicalmechanism of action
is less attractive in a drug than a physiological mechanism. On
the other hand, it seems unlikely that thermogenesis in tissues
other than brown adipose tissue is entirely non-physiological,
because exposure to cold for 4 days increased triacylglycerol/fatty
acid substrate cycling in white as well as brown adipose tis-
sue (Brooks et al., 1983). Other substrate cycles—sometimes
called “futile” cycles—may also be stimulated in the cold, even
though their primary function may not be thermogenesis. UCP-1
knockout mice are able to increase their response to cold expo-
sure when acclimated to cold, and there is evidence that this
is partly due to increased oxidative capacity and ATP utiliza-
tion in white adipose tissue (Meyer et al., 2010; Ukropec et al.,
2006a). Cold exposure (for 2.5 days) also increased fructose-6-
phosphate/fructose-1,6-bisphosphate cycling in skeletal muscle
but this might have been a consequence of shivering in vivo,
even though cycling was measured in vitro (Challis et al., 1985).
On the other hand, when A/J mice were fed on a high fat diet,
soleus muscles taken from them had an increased oxygen con-
sumption, which cannot be attributed to shivering (Kus et al.,
2008). Moreover, mice in which sarcolipin is absent from skele-
tal muscle were less able than wild-type mice to defend their
body temperature in the cold, even when the mice are treated
with curare to prevent shivering, suggesting that futile pump-
ing of Ca2+ may play a role in thermogenesis (Bal et al., 2012).
Finally, it is worth noting that by contrast with the recent
reports that isoprenaline and ephedrine stimulated thermogen-
esis without activating brown fat in humans (Cypess et al., 2012;
Vosselman et al., 2012), noradrenaline stimulated thermogenesis
in both brown adipose tissue and the hind limb (primarily skele-
tal muscle) in rodents (Thurlby and Ellis, 1986), suggesting that
brown fat as well as other tissues is physiologically relevant in
rodents.
Non-sympathomimetic mechanisms
Non-sympatheticmechanisms may also elicit rapid rises in energy
expenditure. Sympathomimetic compounds stimulate thermo-
genesis primarily via β-adrenoceptors and Gαs. One would
therefore expect that activation of any Gαs-coupled receptor in
brown adipose tissue should rapidly activate energy expenditure.
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The bile acid receptor TGR5 is an example of such a receptor.
Agonists of TGR5 increase the concentration of cyclic AMP in
isolated brown adipocytes within 1 h (Watanabe et al., 2006).
Surprisingly, however, a rapid rise in energy expenditure in
response to administration of a TGR5 agonist has not been
described. Instead, the chronic thermogenic activity of TGR5
agonists has been ascribed to increased expression of type 2
iodothyronine deiodinase (D2), which converts thyroxine to tri-
iodothyronine, because the TGR5 agonist cholic acid did not
increase diet-induced thermogenesis in mice that lack D2. This
is not a strong argument because β3-adrenoceptor agonists also
have little thermogenic activity in the absence of a functional
thyroid system (Rubio et al., 1995; Golozoubova et al., 2004).
Activation of AMP-activated protein kinase (AMPK) in
peripheral tissues promotes metabolic pathways that result in
ATP production, whilst inhibiting those that require ATP uti-
lization. Consistent with this role, nootkatone, a constituent of
grapefruit that appears to activate kinases that are upstream of
AMPK, elicited a rapid increase in energy expenditure in mice
that was not associated with increased locomotor activity (Murase
et al., 2010). Similar acute effects have not been described for
directly acting AMPK activators, such as 5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside (AICAR) or the thienopyri-
done A769662; nor for metformin, which activates AMPK by
raising the tissue AMP concentration (Hardie, 2008). However,
both A769662 and metformin reduced the respiratory exchange
ratio (RER) of rats for about 3 h, after which the ratio increased
for about 3 h (Cool et al., 2006), suggesting depletion of fat due
to its increased oxidation or decreased synthesis. Metformin may
cause a slight reduction in body weight in humans (Golay, 2008),
but this seems to be due to decreased energy intake rather than
increased energy expenditure. As in rats, however, metformin
causes a transient reduction in RER (Arch, 2011). By comparison
with other activators of AMPK, the rapid response to nootkatone
is so unusual that it would be logical to check whether it might be
a consequence of sympathetic activation.
Thyroid hormones and possibly fibroblast growth factor 21
(FGF21) are examples of treatments that bridge the gap between
sympathomimetic compounds, which elicit rapid increases in
energy expenditure, and some of the compounds and genetic
modifications that are described in section Detection of Non-
Acute Thermogenesis. In both cases, increased energy expendi-
ture has been dissociated from any discernible effect on body
weight, so it is unlikely that the increase in energy expenditure
was a consequence of a change in body composition.
Depending on the dose, the onset of the response to thyroid
hormones has been reported as 18 h to more than 5 days (Myant
andWitney, 1967; de Lange et al., 2001; Kong et al., 2004). A vari-
ety of mechanisms, involving both decreased efficiency of ATP
production and increased ATP utilization, for example activation
sarcoendoplasmic reticulum Ca2+ ATPase (Silva, 2006; Ukropec
et al., 2006b), have been suggested to explain thyroid-hormone
induced thermogenesis, but it should also be remembered that
thyroid hormones increase thermogenic responsiveness to the
sympathetic nervous system (Ribeiro et al., 2001, 2010), once
again suggesting that the sympathetic nervous system may play
a role in thermogenesis.
FGF21 is released from liver and from brown and white
adipocytes (Muise et al., 2008). Increased energy expenditure per
animal was detected 2 days after intraperitoneal administration of
FGF21 to diet-induced mice (Xu et al., 2009). The thermogenic
effect of exogenous FGF21 may be a consequence of activation of
brown adipose tissue, the induction of genes involved in oxida-
tive metabolism in liver and adipose tissue, and the conversion of
white adipocytes to cells that have some of the characteristics of
brown adipocytes (Xu et al., 2009; Hondares et al., 2010; Fisher
et al., 2012). The development of FGF21 itself as a drug presents
significant challenges but recently workers from Genentech have
described monoclonal antibodies that activate the FGF receptor 1
and have an antidiabetic effect in mice and monkeys (Wu et al.,
2011; Foltz et al., 2012).
Obviously, compounds may elicit rapid rises in energy expen-
diture by promoting motor activity. Speakman (2013) discusses
methods for measuring resting energy expenditure (REE), which
should allow such a mechanism to be excluded.
TECHNICAL ISSUES
The evidence that the compounds described above elicit a rapid
rise in energy expenditure has mostly been obtained using open-
circuit indirect calorimetry. This involves passing air through
a respiratory chamber and comparing its oxygen concentration
after leaving the chamber with that of air entering the chamber
(or leaving a chamber that contains no animals). The difference
in these oxygen concentrations, coupled with the rate flow of air
exiting the chamber cannot be used to measure oxygen consump-
tion accurately because the flow of air into the chamber equals
the flow out only when the RER = 1 (carbohydrate oxidation).
When the RER is 0.72 (fat oxidation), oxygen consumption is
underestimated by 6% if the two flow rates are assumed to be
equal, because flow of air and therefore the amount of oxygen
entering the chamber is higher than assumed. Fortunately, for
the same consumption of oxygen, fat provides 6% less energy
that carbohydrate. Consequently, calculation of energy expendi-
ture assuming that only carbohydrate is being oxidized provides a
very accurate measure of energy expenditure, whatever the bal-
ance of fuels. In other words, thanks to a mathematical fluke,
measurement of oxygen concentration alone gives a more accu-
rate measure of energy expenditure than of oxygen consumption.
If the carbon dioxide concentration of the air leaving the chamber
is also measured, it is possible to determine both carbon diox-
ide production and oxygen consumption and therefore the RER
(Arch et al., 2006).
Changes in energy expenditure in response to specific com-
pounds may bemore rapid than they appear to be in publications.
First, it takes a short time for changes in tissue oxygen utilization
and carbon dioxide production to be reflected in expired air and
then for any of that air to reach the gas analyzers. More impor-
tantly, most authors do not correct their calculation of energy
expenditure to take account of the time that it takes for a change
in energy expenditure to be fully reflected in the composition of
the gases in the respiratory chamber. They ignore the fact that the
volume of oxygen consumed is not only the difference between
that entering and leaving the chamber: the decrease or increase
in the amount of oxygen in the chamber must also be taken into
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account. Similarly, carbon dioxide production is not just the dif-
ference between the amount leaving and entering the chamber.
Assuming perfect mixing of the gases in the respiratory chamber,
the half-life of the approach to the situation where the amount of
oxygen in the chamber is constant after a step change in energy
expenditure is 0.693 × chamber volume/flow rates. It is possible
to calculate instantaneous energy expenditure by applying a cor-
rection derived from the rate of change of the difference between
the oxygen concentration of air entering and leaving the cham-
ber, but this can only be accurate if each chamber is monitored
continuously (Arch et al., 2006; Speakman, 2013).
In our case, we keep animals in their home cages during the
measurement of energy expenditure. If the chamber volume is
20 l and the flow rate is 0.5 l/min, the half-life of the approach
to steady state is 28min—far too long to compare energy
expenditure with instantaneous measures of physical activity.
Moreover, we do not monitor each chamber continuously. Others
use smaller chamber volumes, so this is not so much of an issue.
Nevertheless, it would be helpful if authors would describe both
the chamber volume and the flow rate, and state whether their
calculations of energy expenditure are corrected for the steady
state issue.
SURROGATEMARKERS OF THERMOGENESIS
Not everybody has access to indirect calorimetry. This raises
the question of what measurements might be used as surrogate
markers of thermogenesis. Nothing can substitute for calorime-
try as a quantitative measure of thermogenesis, but an elevation
of the temperature of the heat-producing tissue, ideally rela-
tive to core temperature (Wellman and Marmon, 1985; Yoshioka
et al., 1990), is good indication that thermogenesis is taking place.
Occasionally, brown adipose tissue temperature alone is mea-
sured (Ueta et al., 2012), but measurement of core temperature
alone, being technically easier, is far more common (Malinowska
and Schlicker, 1997; Connoley et al., 1999; Luheshi et al., 1999;
Russell and Tisdale, 2012a). Measurement of core temperature
does not make the assumption that brown adipose tissue is the
site of thermogenesis, but it ignores the possibility that there
is a centrally-mediated increase in the set point of body tem-
perature, as occurs in fever. An increase in body temperature
due to a centrally-mediated increase in the set point of body
temperature might be achieved by means of decreased heat loss
rather than increased energy expenditure. Decreased heat loss
becomes more important at higher ambient temperatures because
it is at these temperatures that skin blood flow and evapora-
tive water loss come into play as cooling mechanisms (Gordon,
2012).
Some workers have combined measurement of core temper-
ature with exposure of animals to cold (typically 4–10◦C). This
approach has helped identify targets for thermogenic drugs in
both brown adipose tissue and muscle (Bal et al., 2012; Fournier
et al., 2012). Another surrogate is increased sympathetic activity,
especially in brown adipose tissue, which has already been men-
tioned as an effect of bone morphogenetic protein 8B (Whittle
et al., 2012).
Increased expression of the UCP1 gene, which may be
detectable at the protein level within a day (Klein et al., 2000) and
much earlier at the mRNA level, has been used by many work-
ers as evidence that brown adipose tissue thermogenesis has been
activated. A note of caution, however: peroxisome proliferator-
activated receptor-γ agonists increase the expression of UCP-1
in brown adipose tissue, but they do not increase thermogenesis
because sympathetic activity is reduced (Festuccia et al., 2008).
Increased expression of UCP-1 is not a reliable indicator of ther-
mogenesis, though it may be a consequence of UCP-1 activation
(Ricquier et al., 2000). Increased binding of GDP to mitochon-
dria isolated from brown adipose tissue is a better indicator of
UCP-1 activation (Trayhurn and Milner, 1989) activation; this
technique also seems to work for skeletal muscle mitochondria
(Yoshida et al., 1998).
DETECTION OF RAPID RESPONSES TO GENETIC MODIFICATION
Detection of the acute effects of genetic manipulations on energy
expenditure presents a significant challenge. It may be possi-
ble to induce genetic manipulation sufficiently rapidly, using for
example a tetracycline-inducible site-specific recombinase sys-
tem such as Cre-loxP, for the effect on energy expenditure to be
assessed before there is a significant change in body composi-
tion (Zhang et al., 2012a). Energy expenditure does not appear
to have been measured in any such animal, however. Another
possible approach involves the use of adenoviral vectors. These
have been used to express a protein that is cleaved to the myokine
irisin in skeletal muscle, and irisin was claimed to increase energy
expenditure (Bostrom et al., 2012). However, it was unclear how
rapidly this effect developed, or whether energy expenditure was
expressed per animal or relative to body weight. In another study,
adeno-associated viral vectors were used to delete the hypothala-
mic CB1-R. Unfortunately energy expenditure was not measured
until long after the body weights of the control and treated
mice had diverged (Cardinal et al., 2012). Therefore, the meth-
ods used to assess whether genetic modification of a potential
drug target affects energy expenditure are limited to non-acute
thermogenesis, as described below.
DETECTION OF NON-ACUTE THERMOGENESIS
CORRECTION FOR DIFFERENCES IN BODY COMPOSITION
It should be more difficult to argue that a compound stimulates
thermogenesis if its effect is not immediate or at least fails to
appear within a day or two. After this time, energy expenditure
might be affected by altered body weight or body composition.
Compounds are more likely to affect lean body mass if animals
are young (Rothwell and Stock, 1988; Arch et al., 1991) but few
studies are conducted in older rodents. If a drug reduces body
weight, especially lean body mass, this may mask its thermogenic
effect. Studies in genetically modified animals present the same
problems. Nevertheless, it is almost routine to read that lean ani-
mals have a higher energy expenditure than their more obese
counterparts. The device used to justify such claims is to express
energy expenditure relative to body weight or body weight0.75.
In the great majority of cases, the researchers then find that the
leaner animals have the higher, mass-specific energy expendi-
ture (Tschop et al., 2012). Those who study energy expenditure
in humans have long-recognized that to understand the role of
energy expenditure in the aetiology of obesity requires a more
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sophisticated approach than this. If rodent data are to be treated
differently from human data there needs to be a justification, but
no such justification has been provided.
Prediction of energy expenditure in humans
The illogicality of dividing energy expenditure in rodents by body
weight or body weight0.75 in order to compare obese with lean
rodents and why this can lead to erroneous conclusions has been
discussed on a number of occasions (Arch et al., 2006; Butler and
Kozak, 2010; Kaiyala et al., 2010; Cannon and Nedergaard, 2011;
Even andNadkarni, 2012; Tschop et al., 2012), including an article
in this issue (Speakman, 2013). We shall not reproduce all these
arguments but wish to demonstrate its absurdity by applying it to
data for humans.
Equation 1 shows the correlation between 24-h energy expen-
diture (24EE; kcal) and body weight (BW in kg) in 177 male and
female subjects with percentage body fat ranging from 3 to 50%
(Ravussin et al., 1986).
24EE = 1043 + 13.0BW (1)
The equation predicts that subjects that weigh 70 kg and 100 kg
(which equate to body mass indices of 22.8 and 32.7 for a height
of 1.75m) will have 24-h energy expenditures of 1953 and 2343
kcal respectively—a 20% higher value in the heavier (and obese)
subject. If 24-h EE is divided by body weight, however, as is com-
mon practice for rodent energy expenditure, we get 27.90 and
23.43 kcal/kg for the 70 and 100 kg subjects respectively—a 16%
lower value in the heavier and more obese subject.
Similar predictions result from equations for REE, thereby
excluding the possibility that differences in energy expenditure
between lean and obese subjects are due to differences in loco-
motor activity.
REE (kcal/d) = 879 + 10.2BW (2)
For example, Equation 2 (Owen et al., 1987) predicts REE values
of 1593 and 1899 kcal/d for 70 and 100 kg men respectively—a
19% higher value in the heavier subject. By contrast, the values
are 22.8 kcal/kg/d and 18.99 kcal/kg/d for the 70 and 100 kg men
respectively—a 17% lower value in the heavier subject. If REE is
expressed relative to body weight0.75, the value is 9% lower in the
heavier subject.
There is some evidence that obese subjects have a lower energy
expenditure than lean subjects, but no workers have claimed
such marked differences. Moreover, they have not used the sim-
plistic approach of dividing energy expenditure by body weight
but have adjusted their data for differences in body composi-
tion (Ravussin et al., 1988; Major et al., 2007). The reason why
energy expenditure per kg body weight is lower in obese subjects
is that fat mass has less influence than fat-free mass (FFM) on
energy expenditure. Note that any influence that fat mass has on
energy expenditure is little to do with the energy required for
triglyceride turnover or even the energy requirements of white
adipose tissue in which the triglyceride is stored, but may be
mainly a consequence of the effects of adipokines, notably lep-
tin, on energy utilization in other tissues (Even et al., 2001;
Kaiyala et al., 2010; Wang et al., 2010b; Kaiyala and Schwartz,
2011).
Equations that relate either total or REE to body composi-
tion (FFM and %fat) demonstrate the greater influence of FFM
compared to fat mass on energy expenditure:
24EE = 488 + 25.8FFM + 4.8% fat (3)
REE (kcal/d) = 560 + 5.39BW + 14.14FFM (4)
Equation 3 (Ravussin et al., 1986) predicts that a subject weighing
70 kg of which 10 kg is fat will have a 24-h energy expenditure of
2104 kg, whereas a subject weighing 100 kg in whom all the extra
weight is fat will have a 24-h energy expenditure of 2228 kcal—a
difference of 124 kcal. On the other hand a muscular 100 kg sub-
ject in which the extra 30 kg is FFM (in total 90 kg FFM; 10 kg
fat) will have a 24-h energy expenditure of 2858 kcal—a differ-
ence of 754 kcal from the 70 kg subject. Thus, extra lean tissue
has 754/124 = 6.1 times the effect of extra fat on 24-h energy
expenditure.
Equation 4 (Horie et al., 2011) predicts differences of 162 and
585 kcal depending on whether the extra tissue in the 100 kg per-
son is due to extra fat or FFM—a 3.6-fold greater contribution
from FFM.
The ratio of 6:1 for the relative contributions of equal weights
of FFM and fat to 24-h energy expenditure is within the range of
5.0–6.7 calculated from experiments in mice for REE (Speakman
and Johnson, 2000; Selman et al., 2001). Others have reported
a ratio as low as 2 for total energy expenditure, which is below
the ratio of 3.6 predicted by Equation 4 for REE in humans.
The Lep◦b/Lep◦b mouse was an exception: fat mass was not a sig-
nificant independent determinant of energy expenditure unless
Lep◦b/Lep◦b mice were injected with leptin, its effect apparently
being to increase the metabolic energy cost of lean body mass
(Kaiyala et al., 2010; Kaiyala and Schwartz, 2011).
Analysis of rodent data
Speakman and other authors have argued that regression mod-
els should be used to compare energy expenditure data between
lean and obese rodents (Arch et al., 2006; Kaiyala and Schwartz,
2011; Tschop et al., 2012; Speakman, 2013). The simplest regres-
sion method is to use analysis of covariance (ANCOVA) to relate
energy expenditure to body weight for the whole data set—both
control and treated or genetically altered groups. Energy expendi-
ture values are shifted in parallel with the slope of the regression
line to the mean body weight for the whole data set and then
compared between groups (Speakman, 2013). More sophisticated
methods involve multiple regression, for example separating out
fat mass and lean body mass. It may be even better to separate out
components of lean body mass, especially skeletal muscle mass,
because this makes a relatively low contribution per unit mass
to resting metabolic rate (Even et al., 2001). However, the more
components that are included in the analysis, the lower its power
to detect differences (Even and Nadkarni, 2012).
Regression analysis is undoubtedly more rigorous than divi-
sion of energy expenditure by body weight, body weight0.75 or
even lean body mass. It shows whether differences in energy
expenditure might be explained by the effect of a treatment or
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genetic manipulation on body size or composition (“repartition-
ing,” which is discussed further below). It may not always be
possible to obtain information on body composition, however,
especially components of lean body mass, during the in-life phase
of a study. Other problems for some data sets are discussed in
detail by Speakman (2013). One is that weights used for the
regression analysis may not overlap sufficiently between treat-
ment groups or genotypes. Consequently, the regression line may
simply join the mean energy expenditure values for the two data
sets, so that at each end there are equal numbers of points above
the regression line. This inevitably leads to the conclusion that
the data set belong to the same regression line. A wider range of
weights might give a steeper slope with energy expenditure val-
ues for animals from the leaner group tending to lie above the
line and those for the fatter group below the line. This problem is
more likely to occur with small data sets.
A possible solution might be to fix the slope of the regression
line using information for a larger number of animals of the same
control and test types, rather than using data from the smaller
experiment being analyzed. This would require that the slopes are
similar for animals of the types being compared. Biologists take
such an approach routinely when they use parametric statistics
to compare data sets where n < 5, because it is only when n ≥ 5
that it can be shown with reasonable power using Bartlett’s test
whether data have similar variances (exhibit homoscedasticity).
Fortunately, we are allowed to use parametric statistics if previous
work shows that similar data sets have similar variances (possible
after transformation). Without this rule, we could never say that
the data sets 1, 2, 3, and 1001, 1002, 1003 are significantly differ-
ent because the non-parametricMann–Whitney two-sidedU-test
gives P = 0.1.
Even if body weights or the weights of body components over-
lap, small data sets increase the probability that the regression
line will not be significant, especially if weights of individu-
als are similar in each group. It has been argued that in such
cases it is acceptable to divide energy expenditure by lean body
mass because it contributes more than fat mass to whole body
energy expenditure (Butler and Kozak, 2010). Fat mass cannot
be ignored, however, and Speakman (2013) argues that dividing
energy expenditure by lean body mass does not increase the power
to separate data sets.
This raises the point that the great majority of studies on the
effect of genetics on energy expenditure have been underpow-
ered (Tschop et al., 2012; Speakman, 2013). Some workers have
gone so far as to suggest that indirect calorimetry is not suffi-
ciently accurate to be of value in long term studies of energy
balance (Even and Nadkarni, 2012). Whilst true in many cases,
there may be a few mechanisms, such as those that impact on
sympathetic activity or the response of brown adipose tissue to
sympathetic activity, that have sufficiently large effects for differ-
ences in energy expenditure to be detected. For example, in our
hands the Lep◦b/Lep◦b mouse had a lower energy expenditure per
animal thanwild-typemice, but only at a temperature below ther-
moneutrality (Trayhurn and James, 1978; Wilson et al., 1984). In
addition, pair-feeding studies in which young Lep◦b/Lep◦b mice
were yoked to the ad libitum energy intake of their lean sib-
lings became obese, reflecting a lower level of energy expenditure,
and these differences were much less marked at thermoneu-
trality than at lower environmental temperatures (Thurlby and
Trayhurn, 1979). This phenotype may be due to the Lep◦b/Lep◦b
mouse not raising sympathetic activity adequately in response to
cold (Reichling et al., 1988). [Others have found that Lep◦b/Lep◦b
mice have a higher energy expenditure than their wild type con-
trols possibly because they measured energy expenditure under
different conditions (Himms-Hagen, 1997; Butler and Kozak,
2010)].
The Lep◦b/Lep◦b mouse is of course an example of an obese
mutant, whereas the focus of this article is leanness. It is therefore
disappointing that energy expenditure has not been measured
in “skinny” mice, which overexpress leptin, although increased
insulin sensitivity has been described (Ogawa et al., 1999). Mice in
which the soluble leptin receptor was overexpressed had increased
energy expenditure relative to lean body mass, but they also had
lower amounts of both lean and fat mass, making interpretation
of this finding difficult for reasons explained above (Lou et al.,
2010).
In those cases where the data are not suitable for analysis
using regression models, the best solutionmay be to adjust energy
expenditure data according to the size of key organs using fac-
tors described in the literature (Elia, 1992; Even et al., 2001; Wang
et al., 2010a,b). An interesting suggestion is that energy expen-
diture for mice of differing adiposities might be divided by lean
body mass plus 0.2× fat mass (Even and Nadkarni, 2012). This
is consistent with one of the reports discussed above (Selman
et al., 2001), which suggested that, relative to its weight lean, body
mass contributes five times more than fat mass to energy expen-
diture. This approach is not ideal, however, and must not be used
thoughtlessly, especially in animals that lack a functional leptin
system (Kaiyala et al., 2010) As mentioned in section Prediction
of Energy Expenditure in Humans, the influence that adipose tis-
sue has on energy expenditure may be mainly a consequence of
the effects of adipokines on energy expenditure in other tissues,
so the consequences of manipulating adipokine secretion must
be considered.
NON-ACUTE STIMULATION OF ENERGY EXPENDITURE PER ANIMAL
Repartitioning
There is little difficulty in arguing that a compound is ther-
mogenic, or a genetically modified mouse suggests a target for
thermogenic drugs if energy expenditure per animal is increased,
whilst body fat is decreased (or at least unchanged) and lean tissue
is not increased. A compound that increases energy expenditure
per animal because it increases the proportion of more metabol-
ically active organs, such as liver or brain, relative to skeletal
muscle might be better described as a repartitioning or anabolic
agent, rather than a thermogenic drug. A possible example from
our own work is the 11β-hydroxysteroid dehydrogenase type 1
inhibitor BVT.2733, which increased both lean body mass and
energy expenditure (Wang et al., 2006). The comparison in this
example was with pair-fed mice because BVT.2733 reduced food
intake and so its effect was to prevent the loss of lean tissue in
response to reduced food intake.
Genetic modifications that increase energy expenditure per
animal because they alter body composition may suggest targets
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for repartitioning agents. Thus, in our own work, both lean
body mass and energy expenditure were higher in male acyl
CoA:diacylglycerol acyltransferase 1-null than in wild-type mice
when the mice were fed on a high fat diet (Wang et al., 2007).
Some compounds or genetic modifications may increase energy
expenditure due to both a repartitioning effect and a thermo-
genic effect that is independent of the repartitioning effect. For
example, the β2-adrenoceptor agonist clenbuterolmay cause ther-
mogenesis in obese (fa/fa) rats by stimulating brown adipose
tissue and by repartitioning energy to skeletal muscle (Rothwell
and Stock, 1987).
Non-acute thermogenesis in response to compounds
β3-Adrenoceptor agonists and FGF21 are examples of treatments
that increase energy expenditure per animal when they are given
for a week or more, even though body fat content is by this
time decreased and body lean content is not increased (Arch and
Ainsworth, 1983a; Xu et al., 2009). Leptin may also have increased
energy expenditure per animal when given for more than a week
to rat pups, though data were expressed relative to body weight,
which may have decreased slightly (Stehling et al., 1996). In adult
mice, leptin had a more subtle effect that developed over days: it
reduced the daily minima of energy expenditure when the mice
were food restricted (Doring et al., 1998). Chemical sympathec-
tomy reduced weight loss in response to intracerebroventricular
infusion of leptin by 60% over 10 days in rats, despite it not affect-
ing the response of food intake to leptin (Dobbins et al., 2003).
This suggests that weight loss was partly due to thermogenesis
driven by the sympathetic nervous system. It is consistent with
the thermogenic effect of leptin on days 2–6 being reduced by
about 50% inmice that lack all three β-adrenoceptors (see section
Acute Stimulation of Energy Expenditure). However, the same
paper reports that leptin did not cause weight loss over 6 days
in either wild type or “β-less” mice other than by reducing food
intake (Asensio et al., 2008).
The examples discussed so far are all treatments that
also increase energy expenditure almost immediately (β3-
adrenoceptor agonists) or at least within 2 days (FGF21; leptin).
It is much more difficult to find examples of compounds that
increase energy expenditure per animal after more than 2 days but
not earlier (without increasing lean body mass). B- and C-type
natriuretic peptides (BNP and CNP), which activate receptors
that are linked to guanylyl cyclases, seem to promote thermogen-
esis in brown adipose tissue. BNP increased oxygen consumption
per mouse after it had been infused for 7 days but its acute
effect was not reported (Inuzuka et al., 2010; Bordicchia et al.,
2012).
Most claims of increased energy expenditure in lean animals
are shown to be ill-founded on detailed examination. For exam-
ple, antagonism of the activin receptor IIB by immunological
means has been claimed to increase energy expenditure either by
increasing muscle mass or by increasing brown adipocyte adipo-
genesis (Fournier et al., 2012; Koncarevic et al., 2012). Energy
expenditure was measured after 28 or 60 days, however, and
expressed relative to body weight, which in at least one of these
studies (Koncarevic et al., 2012) was decreased in proportion
to the increase in energy expenditure per gram body weight.
Another recent example is JD5037, which is a CB1-R inverse ago-
nist that has poor brain penetration. JD5037 reduced food intake
and body weight in diet-induced obese mice (Tam et al., 2012).
It was claimed that it increased energy expenditure, but this was
expressed relative to body weight0.75 and it can be calculated that
the ratio of the oxygen consumption values in treated and con-
trol mice on day 21 of treatment is very similar to the inverse
of the ratio of the body weight0.75 values at that time. In other
words, energy expenditure per mouse was not altered by treat-
ment. JD5037 affects body weight by reversing leptin resistance
and leptin increases sympathetic activity, so it would not have
been surprising if it had increased energy expenditure per mouse.
However, JD5037 reverses leptin resistance by reversing hyper-
leptinaemia, which would tend to lower sympathetic activity.
Thus, the lower concentration of leptin and the increased sensi-
tivity to leptin may have had roughly equal and opposing effects
on energy expenditure. [It is worth noting that leptin expression
and release is inhibited by the sympathetic nervous system, so
leptin production as well as responsiveness to leptin is subject to
feedback control (Mantzoros et al., 1996; Trayhurn et al., 1996)].
The AMPK activator AICAR increased energy expenditure per
animal after 4 and 8 weeks’ administration to rats compared to
pair-fed control (Gaidhu et al., 2011). Energy expenditure was
measured weekly and there is no evidence given in this paper
or elsewhere of it having an earlier or acute thermogenic effect
(although an acute lowering of RER was described in section
Acute Stimulation of Energy Expenditure). Thus, AICAR may be
an example of a treatment whose thermogenic effect takes more
than a week to develop. AICAR also reduced fat pad weights com-
pared to the pair-fed controls, which suggests that weight loss may
have been due to thermogenesis; but if so it is surprising that fat
mass increased at the same rate as in controls between 4 and 8
weeks of treatment even though thermogenesis did not diminish.
The effect of AICAR was not that expected for a peripherally act-
ing AMPK activator because energy expenditure increased only
during the dark period and was associated with increased loco-
motor activity. It is well-established that activation of AMPK in
the hypothalamus increases food intake, which raises the possi-
bility that increased locomotor activity elicited by AICAR may
have been due to enhancement of food seeking behavior. In the
light of this discussion the conclusions of a recent review are
of interest. These were that AMPK is “always activated by mito-
chondrial uncoupling” mediated by UCP-1, and may augment
the effect of uncoupling but “activation of AMPK alone does not
lead directly to an induction of energy expenditure (Klaus et al.,
2012).”
Non-acute thermogenesis in response to genetic modifications
The UCP-1 knockout mouse is an example of a genetic modifi-
cation that elicits (paradoxically) a detectable increase in energy
expenditure per animal. This difference could not be detected
until the ambient temperature had fallen to about 10–12◦C, how-
ever. It seemed to be due to the mouse being forced to use a
mechanism independent of UCP-1 to generate heat. This mecha-
nism must be less efficient than UCP-1 activation in maintaining
body temperature (Ukropec et al., 2006a). Another example is
the melanin-concentrating hormone 1 receptor knockout mouse,
Frontiers in Physiology | Integrative Physiology April 2013 | Volume 4 | Article 64 | 8
Arch and Trayhurn Detection of thermogenesis in rodents
but in this case the increase was associated with increased loco-
motor activity (Marsh et al., 2002). The renin knockout mouse
displayed an increased energy expenditure relative to its lean body
mass, and at least in the case of REE, it seems likely that energy
expenditure per mouse was raised (Takahashi et al., 2007).
These are rare examples. An example that does not stand up to
scrutiny is that overexpression of FGF19 increases energy expen-
diture (Tomlinson et al., 2002). It was only energy expenditure
expressed relative to body weight0.75 that was increased. Once
again it can be calculated from the data presented that energy
expenditure per animal was no different between transgenic and
wild-type mice. The authors also argued that energy expenditure
must have been increased because food intake was higher in the
transgenic mice, but food intake was expressed relative to body
weight (not like energy expenditure as body weight0.75) and it was
not increased on a whole animal basis.
We have already argued that exogenous FGF21 has a thermo-
genic effect. This was detectable after 19 days of treatment (Xu
et al., 2009). It is perhaps therefore surprising that energy expen-
diture expressed relative to body weight was similar in mice in
which FGF21 was overexpressed and wild-type mice, even though
the FGF21 overexpressing mice were much smaller. Thus, energy
expenditure per animal was lower in the transgenic mice in pro-
portion to their weight. However, the body composition of the
transgenic and wild-type mice was similar, so this is not a com-
parison between a lean and an obese strain. It appears instead to
be a situation where energy expenditure really does reflect body
size (Zhang et al., 2012b).
There are a few examples of where the correlation between
energy expenditure and body weight has been shown to be altered
by genetic modification. Some of these involve modifications
that affect the development and function of brown adipose tis-
sue. Thus, ANCOVA showed that energy expenditure at a given
body weight was increased in mice with a null mutation for tran-
sient receptor potential vanilloid 4 (TRPV4). An antagonist of
TRPV4 increased the expression of UCP-1 in brown adipose tis-
sue, but its effect on energy expenditure was not reported (Ye
et al., 2012). Mice in which UCP-1 was overexpressed in skele-
tal muscle were leaner than wild-type mice (unlike the UCP-1
knockout mice, this is predictable rather than paradoxical). Mean
energy expenditure was not increased, but for a given body weight
it was higher in the genetically modified animals (Couplan et al.,
2002). It might be argued that this was because the weights of
the brain and liver—organs that make a disproportionate con-
tribution to energy expenditure—were increased. However, other
work showed that energy expenditure (which was expressed rel-
ative to body weight) was increased at night but not during
the day, despite there being no difference in locomotor activ-
ity between the wild-type and transgenic mice. Daytime energy
expenditure was, therefore in effect, a within-animal control for
night-time energy expenditure. The authors therefore concluded
that muscle energetic efficiency was decreased by over-expression
of UCP-1 in skeletal muscle (Klaus et al., 2005). The fact that acti-
vation of UCP-1 is the mechanism of thermogenesis in brown
adipose tissue seems to support the view that this is a genuine
example of a genetic modification that stimulates thermogenesis,
but as mentioned previously, the expression of UCP-1 indicates
only the capacity for thermogenesis in brown adipose tissue and
not whether this capacity is being used. Other examples of the
effect of overexpression of UCP-1 in skeletal muscle, white adi-
pose tissue and liver have been reviewed recently in relation to
the role of AMPK in mediating the phenotype (Klaus et al.,
2012).
INDIRECT EVIDENCE
It may be possible to deduce that a compound or genetic modifi-
cation has increased energy expenditure without directly measur-
ing expenditure itself. One such situation is where energy intake
is increased and yet the treated or genetically modified animal has
a reduced body fat content and no increase in lean body mass. For
example, repeated administration of the β3-adrenoceptor ago-
nist BRL26830 increased food intake in lean mice but reduced
their body lipid content and had no effect on lean body mass
(Arch and Ainsworth, 1983b). In this instance it was also appar-
ent from indirect calorimetry that energy expenditure per animal
was elevated. Similarly, 11β-hydroxysteroid dehydrogenase type
1 knockout mice fed on a high fat diet were less obese than
wild-type mice, despite having a higher caloric intake (Morton
et al., 2004). Their increased core temperature also suggested
that energy expenditure was raised. By contrast, increased energy
expenditure per animal was not evident inmice that lacked acetyl-
CoA carboxylase-2, but it appeared that energy expenditure must
have been increased because the knockout mice consumed more
energy than the wild-type mice but had a reduced body fat
and lean content (Abu-Elheiga et al., 2001; Choi et al., 2007).
The knockout mice showed increased energy expenditure rela-
tive to lean body mass, but it can be calculated from the data
provided that energy expenditure per animal was no different
between the knockout and control mice (Choi et al., 2007). It
is difficult to understand how energy intake per mouse could
have been so much higher (20–30%) in the knockout than the
wild-type mice and yet energy expenditure per mouse was not
increased. Other workers have failed to replicate these findings
(Hoehn et al., 2010; Olson et al., 2010). Nevertheless, the prin-
ciple that it may be possible to deduce from energy intake and
body composition that energy expenditure has increased remains
valid. This assumes, of course, that the food eaten is absorbed
normally and energy is not lost as a result of glycosuria or keto-
sis; in other words, that the metabolisability of the diet is not
altered.
Another situation that might suggest increased thermogene-
sis is where body fat content is reduced, but there is no decrease
in food intake, or food intake is kept equal between groups by
pair-feeding. The problem with this argument is that it is easier to
show that body fat content differs between two groups of animals
than that their energy intake (especially energy absorption) dif-
fers. Without positive evidence of increased energy expenditure
such arguments are usually unreliable. A similar argument is that
drugs that are both acutely thermogenic and acutely anorectic
cause fat loss in the longer term through thermogenesis, because
the effect on food intake usually wanes rapidly and food intake
over the whole course of the study is not reduced (Arch, 1981;
Day and Bailey, 1998; Picard et al., 2000; Billes and Cowley, 2008;
Herling et al., 2008). This logic is of little value, however, unless it
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is demonstrated that the thermogenic effect of the treatment does
not disappear in the same way that the anorectic effect disappears.
One instance where the thermogenic effect of treatment did
not disappear was when the Lep◦b/Lep◦b mouse was dosed
repeatedly with a β3-adrenoceptor agonist (Arch and Ainsworth,
1983a). The Lep◦b/Lep◦b mouse is amenable to such a finding
because it has low sympathetic activity at temperatures below
thermoneutrality and it has a lot of fat to lose. Their lean
littermates do not have as much fat in their whole body as
the Lep◦b/Lep◦b mouse loses in response to treatment with β3-
adrenoceptor agonists for a month. Consequently, since lean body
mass is not reduced, lean mice must either have a reduced ther-
mogenic response as treatment continues or they must increase
their energy intake (Arch and Ainsworth, 1983a). Unfortunately,
the Lep◦b/Lep◦b mouse is not a good general model of human
obesity because it lacks leptin, and this has many downstream
consequences—low sympathetic activity and high hypothala-
mic neuropeptide Y release, for example. Thus, any intervention
that corrects leptin deficiency or any of its downstream conse-
quences is likely to have an exaggerated effect in the Lep◦b/Lep◦b
mouse.
Full carcass analysis coupled with careful measurement of
metabolisable energy intake is occasionally used to calculate
energy expenditure (Dulloo and Miller, 1987; Mercer and
Trayhurn, 1987). Ideally, such studies should be conducted using
metabolic chambers and faecal and urinary energy should be
measured. This approach has been used to demonstrate that the
β2-adrenoceptor agonist clenbuterol increases thermogenesis as
well as increasing lean tissue at the expense of fat (Rothwell and
Stock, 1987).
TRANSLATION OF RODENT FINDINGS TO HUMANS
It is important to understand how, and when (i.e., under
what conditions), a compound increases energy expenditure in
rodents before investigating whether it does the same in humans.
Similarly, it is sensible to know how a genetic modification
increases energy expenditure before seeking drugs that act via the
product of the modified gene. An obvious example of the “how”
issue is where thermogenesis is associated with increased locomo-
tor activity. Whether this is an acceptable mechanism of action
for an antiobesity drug is debatable, but it clearly would make
no sense to expect energy expenditure to be raised in humans
when they are resting. Thyroid hormone-related mechanisms
raise the spectre of cardiac stimulation, loss of skeletal muscle,
bone wasting, fatigue, and CNS effects (Crunkhorn and Patti,
2008), although there has been interest in the possibility that
selective activators of thyroid hormone receptor-β might avoid
such problems (Ribeiro, 2008).
The significance of the “when” question can be illustrated by
the influence of ambient temperature on the phenotype of the
UCP-1 knockout mouse. The phenotype of these mice appears to
depend on whether they are housed at thermoneutrality or below
thermoneutrality. Reports vary, however, from the UCP-1 knock-
out mouse being obese and especially sensitive to diet-induced
obesity when housed at thermoneutrality (Feldmann et al., 2009),
to their being resistant to diet-induced obesity when housed at
20◦C (Liu et al., 2003). Most humans live at temperatures near
thermoneutrality, which suggests that, if anything, activation of
UCP-1 in brown adipose tissue, rather than its absence should
increase whole body thermogenesis. However, there is the possi-
bility that less efficient thermogenic mechanisms in other tissues
might shut down when brown adipose tissue is activated, entirely
negating the effect of UCP-1 activation.
A common situation is that a compound increases energy
expenditure because it increases the activity of the sympathetic
nervous system. Activation of the sympathetic nervous system
in humans has far less effect on energy expenditure in humans
than in rodents. The maximum increase in energy expenditure
in humans at thermoneutrality in response to sympathomimetic
drugs is about 30% (Schiffelers et al., 2000, 2001), whereas in
rodents increases of two- or threefold are possible if the animals
are maintained at around 21◦C (Wilson et al., 1984; Wernstedt
et al., 2006; Feldmann et al., 2009). Even greater fold increases
are possible if the animals are maintained at thermoneutrality to
suppress their baseline sympathetic activity. This also applies to a
centrally acting agent such as ephedrine: it should not be assumed
that centrally acting drugs cannot raise sympathetic activity if
rodents or humans are at thermoneutrality (Wilson et al., 1984;
Gordon, 2012). It is important to remember that the thermoneu-
tral zone may be lowered if animals are housed in groups so that
they can huddle, or if they are given plenty of bedding to wrap
up in or a wheel to keep active; this is reflected in the differences
in thermogenic activity and capacity of their brown adipose tis-
sue when mice are housed singly or in groups of varying size
(Jennings et al., 1986). Large effects may also occur in Lep◦b/Lep◦b
mice and similar models of leptin dysfunction, which have low
sympathetic activity (Wilson et al., 1984). Indeed, it is possible
that increased energy expenditure might not translate at all from
such models to humans.
To give some perspective on thermogenesis in humans, a sim-
ple calculation shows that anorectic drugs must alter energy
balance by about 10% to cause weight loss of about 5 kg over six
months, which historically has been a typical effect (Rucker et al.,
2007). It may be difficult to achieve this over 24 h if the maxi-
mum effect is 30%. On the other hand, despite their relatively low
efficacy as stimulants of energy expenditure, sympathomimetic
drugs, such as β-adrenoceptor agonists, have been shown to
improve insulin sensitivity markedly in humans (Mitchell et al.,
1989; Smith et al., 1990).
What if a compound does increase sympathetic activity in
humans? Might it have undesirable side-effects due to general-
ized sympathetic activation? This was the case with sibutramine.
It is unclear whether thermogenesis contributed to its antiobesity
effect, but sympathetic activity contributed to the cardiovascu-
lar side effects that eventually led to its withdrawal (James et al.,
2010). The thermogenic effect of rimonabant, by contrast, was
not detected in humans, although another CB1-R antagonist did
raise energy expenditure (Addy et al., 2008).
A drug that raises sympathetic activity selectively in brown
adipose tissue, skeletal muscle or white adipose tissue, rather
than in the cardiovascular system would be ideal, but is this
feasible? Despite evidence that sympathetic nerves to brown adi-
pose tissue can be activated selectively (Morrison, 2001; Kosari
et al., 2011), leptin, the main role of which is to regulate energy
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balance, raises sympathetic activity in “non-metabolic” tissues
(Haynes et al., 1997; Rahmouni and Morgan, 2007). The current
interest in drugs and drug targets that increase the response of
brown adipose tissue to the sympathetic nervous system offers a
possible way to avoid these problems.
CONCLUSION
As long as we seek drugs for the treatment of obesity, the ques-
tions, “Is it thermogenic?” and “Is it a target for thermogenic
drugs?” will continue to be asked. It is a relatively simple matter
to show whether a compound stimulates thermogenesis if energy
expenditure increases rapidly and cannot be a consequence of
altered body composition. The clearest examples of such com-
pounds are those that activate or mimic the sympathetic nervous
system, and so it is wise to check whether any compound whose
effect appears rapidly acts via such a mechanism.
Even if a compound has an anti-obesity effect and is acutely
thermogenic, it cannot be assumed that this is why it causes
weight loss unless it raises 24-h energy expenditure throughout
the weight loss experiment. This then raises an issue that also
afflict studies in which potential drug targets are genetically mod-
ified in mice: how should energy expenditure be expressed. The
wrong way, at least when comparing lean and obese mice, is to
divide energy expenditure by body weight or body weight0.75. The
surest way is to express energy expenditure per mouse and then to
check whether energy expenditure has increased because there is
an increase in the absolute amount of lean tissue—in other words
the treatment would be better described as “repartitioning” rather
than thermogenic.
There are other ways of detecting thermogenesis than measur-
ing energy expenditure, and there are ways of comparing energy
expenditure measurements that allow for differences in body
weight and composition, but they should not be used without an
understanding of their limitations.
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